TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review.
Fiche publication
Date publication
septembre 2020
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
The association between tumor necrosis factor inhibitors (TNFi) and malignancy in patients with inflammatory bowel disease (IBD) is not well understood. Our aim was to systematically evaluate the impact of TNFi use on risk of malignancy in IBD-patients in daily clinical practice.
Mots clés
TNF inhibitors, cancer, inflammatory bowel disease, malignancy
Référence
J Crohns Colitis. 2020 Sep 11;: